Keyphrases
Chemotherapy
100%
Urothelial Carcinoma
100%
Pembrolizumab
100%
Platinum-refractory
100%
Progressive Disease
50%
Objective Response Rate
30%
Paclitaxel
30%
Gemcitabine Plus Cisplatin
30%
Cisplatin
20%
Methotrexate
20%
Clinical Benefit
20%
Vinblastine
20%
Metastatic Urothelial Carcinoma
20%
Gemcitabine
10%
Overall Survival
10%
Median Overall Survival
10%
Clinical Factors
10%
Programmed Death-ligand 1 (PD-L1)
10%
Adriamycin
10%
Carboplatin
10%
First-line Chemotherapy
10%
Survival Outcomes
10%
Logistic Regression
10%
Propensity Score Matching
10%
Programmed Death Ligand
10%
Best Supportive Care
10%
Platinum Sensitivity
10%
Platinum Agents
10%
Propensity Score Model
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Transitional Cell Carcinoma
100%
Pembrolizumab
100%
Disease
50%
Cisplatin
50%
Gemcitabine
40%
Paclitaxel
30%
Overall Survival
20%
Methotrexate
20%
Vinblastine
20%
Doxorubicin
10%
Carboplatin
10%
First-Line Chemotherapy
10%
Insulin
10%
Programmed Death 1 Receptor
10%
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Pembrolizumab
100%
Cisplatin
50%
Progressive Disease
50%
Gemcitabine
40%
Paclitaxel
30%
Overall Survival
20%
Methotrexate
20%
Vinblastine
20%
Logistic Regression Analysis
10%
Supportive Care
10%
Doxorubicin
10%
Programmed Death-Ligand 1
10%
Carboplatin
10%
First-Line Chemotherapy
10%
Propensity Score Matching
10%
Insulin
10%
Programmed Death 1 Receptor
10%